using standard-of-care procedures), the site is initiated in an expedited manner. In spite of the challenges involved in clinical trials for patients with rare cancers, Just-In-Time continues to demonstrate that US-based studies can accrue efficiently, while significantly mitigating cost and time related risks. This methodology represents an important step toward a more effective clinical trial system, aligned with the needs of precision cancer treatment. Just-In-Time continues to evolve, setting a new standard for time to first patient enrolled, enrollment rate, and overall patient accrual.
Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides oncology-specific Site Management Organization (SMO) and Contract Research Organization (CRO) services to its network of primarily community-based clinics. While experienced in oncology studies, the company's separate Data Management business entity is also capable of providing services for research projects in other disease indications. Pharmatech Oncology's dedication to rapid enrollment and quality data ensures successful development and utilization of therapeutic products among sponsors, investigators, and patients.
About Pharmatech Oncology, Inc.:
Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides oncology-specific Site Management Organization (SMO) and Contract Research Organization (CRO) services to its network of primarily community-based clinics. While experienced in oncology studies, the company's separate Data Management business entity is also capable of providing services for research projects in
'/>"/>
SOURCE Pharmatech Oncology, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 20072.
WuXi PharmaTech Announces Second Quarter 2007 Results3.
WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia4.
WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China5.
Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech6.
Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology7.
WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO8.
WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.9.
WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs10.
Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer11.
WuXi PharmaTech Completes Acquisition of AppTec